|
ISPOR
Fourth Annual European Conference
11-13 November 2001
Noga Hilton Cannes, Cannes, France
During the ISPOR Fourth Annual European Congress, 11-13 November 2001
Noga Hilton Cannes, Cannes, France, the scientific merit exhibited in
contributed poster and podium presentations was recognized with awards given
by authors' groups: general, students and new investigators. This year, the
ISPOR Awards Committee evaluated approximately 48 podium presentations and
over 250 poster presentations.
A SPECIAL THANKS GOES TO PROF. DR. LIEVEN ANNEMANS , CHAIR OF THE FOURTH ANNUAL EUROPEAN
CONGRESS AWARDS TASK FORCE COMMITTEE AND HIS COMMITTEE FOR ALL THEIR EFFORTS
IN SELECTING THE WINNERS.
And the winners are...
ISPOR Best Contributed Podium
Presentation Award
BEST GENERAL PODIUM PRESENTATION
DB1
ESTIMATING HEALTH CARE-COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS
USING DATA FROM THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS)
Gray A, Clarke P, University of Oxford,
Oxford, UK
IN2
THE ECONOMIC BURDEN OF VIRAL RESPIRATORY INFECTION IN THE UNITED STATES
Fendrick AM1, Sarnes MW2, Nightengale B2, Monto AS1
1University of Michigan, Ann Arbor, MI, USA; 2Applied Health Outcomes, Tampa,
FL, USA
CE1
IMPACT OF CENSORED COST DATA ON THE OUTCOMES OF ECONOMIC EVALUATIONS
Oostenbrink JB, Al MJ, Rutten-van Mölken MM
Institute for Medical Technology Assessment, Rotterdam, Netherlands
BEST NEW INVESTIGATOR PODIUM PRESENTATION
QL2
ESTIMATING PATIENTS´ PREFERENCES IN TREATMENT CHOICES INVOLVING RISK: A NEW
MODIFIED STANDARD GAMBLE METHOD
Walshe R, University of Cologne, Cologne,
Germany
ND2
ASSESSING THE QUALITY OF LIFE IN PARKINSON'S DISEASE
Spottke AE1, Reuter M1, Smala A2, Berger K2, Athen
O3, Köhne-Volland R3, Meyer D3, Oertel WH1, Dodel RC1
1Philipps-University Marburg, Marburg, Germany; 2MERG - Medical Economics
Research Group, Munich, Germany; 3Metronomia, Munich, Germany
CH1
DEVELOPMENT OF A MINIMUM DATASET (MDS)-BASED COMORBIDITY INDEX FOR A NURSING
HOME POPULATION
Gilsenan A, RTI Health Solutions, Research
Triangle Park, NC, USA
BEST STUDENT PODIUM PRESENTATION
HP5
USE OF THE SOJA METHOD FOR CHOOSING A HMG CO-A REDUCTASE INHIBITOR (STATIN) IN
IRELAND
Heerey A, McGowan B, Barry M National
Centre for Pharmacoeconomics, Dublin, Ireland
HP1
VALIDITY OF THE MINIMUM-DATA-SET-BASED QUALITY INDICATOR FOR DETERMINING THE
PREVALENCE OF ANTIPSYCHOTIC MEDICATION USAGE AMONG LOW RISK NURSING HOME
RESIDENTS: A STATEWIDE ASSESSMENT
Monroe DM1, Cortes LL2, Fouladi R3
1The University of Texas at Austin, Austin, TX, USA; 2Texas Department of
Human Services, Austin, TX, USA; 3The University of Texas at MD Anderson
Cancer Center, Houston, TX, USA
ISPOR Best Contributed
Poster Presentation Award
BEST GENERAL POSTER PRESENTATION
PMI6
ESTIMATING AND COMPARING RESOURCE USE AND COST OF G-CSF USE IN CHEMOTHERAPY
WITH THE ACTIVITY-BASED COSTING (ABC) METHOD IN 3 SETTINGS
Annemans LJ1, Vanoverbeke N2, Caekelbergh K2, Van
Belle S3, Cocquyt V3, Standaert B4
1Ghent University, HEDM, MEISE, Belgium; 2HEDM, MEISE, Belgium; 3Ghent
University Hospital, GENT, Belgium; 4Amgen Inc, Brussels, Belgium
PMI2
SMOOTHED BOOTSTRAP FOR CONFIDENCE INTERVAL FOR COST-EFFECTIVENESS RATIOS
Lenne X, Lebrun T, CRESGE-LABORES, LILLE,
France
PDG27
HEALTH STATE UTILITIES IN GERD PATIENTS WITH HEARTBURN; A STUDY IN GERMANY AND
SWEDEN
Kartman B1, Gatz G2, Johannesson M3
1AstraZeneca R&D, Mölndal, Sweden; 2Byk Gulden, Konstanz, Germany; 3Stockholm
School of Economics, Stockholm, Sweden
MI4
MARKOV MODELLING TO CONVERT TRIAL-BASED COST-EFFECTIVENESS INFORMATION TO
OTHER COUNTRIES; THE TIOTROPIUM EXAMPLE
Oostenbrink JB, Rutten-van Mölken MP
Institute for Medical Technology Assessment, Rotterdam, Netherlands
BEST NEW INVESTIGATOR POSTER PRESENTATION
PAO8
THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS
Barbieri M1, Wong JB2, Drummond MF3
1University of York, York, UK; 2Tupper Research Institute, New England Medical
Center, Boston, MA, USA; 3University of York, York, UK
PCN16
ELAPSED TIME TO DISCLOSURE OF BRCA1/2 GENETIC TESTING RESULTS AND
PARTICIPANTS' DISTRESS: PRELIMINARY FINDINGS FROM A RESEARCH SETTING
Dorval M1, Maunsell E1, Morel S1, Dugas MJ2, Simard
JR1
1Université Laval, Québec, QC, Canada; 2Concordia University, Montréal, QC,
Canada
PDG18
TREATMENT CHANGE FOLLOWING HEMOGLOBIN A1C TEST RESULTS AMONG DIABETIC PATIENTS
Schabert V1, Zhang M2, Esposito D1, Neslusan C2,
Conklin J1, Cohen F3
1The MEDSTAT Group, Santa Barbara, CA, USA; 2Pharmaceutical Group Strategic
Marketing, Raritan, NJ, USA; 3R.W. Johnson Pharmaceutical Research Institute,
Raritan, NJ, USA
BEST STUDENT POSTER PRESENTATION
PAO2
ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS
Lovas K1, Szende A2, Hodinka L3, Bàlint G3, Héjj G3
1Semmelweis University, Budapest, Hungary; 2AstraZeneca, Torokbalint, Hungary;
3National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
PHP12
BARRIERS THAT PREVENT THE USE OF ECONOMIC EVALUATIONS IN HOSPITAL FORMULARY
DECISION-MAKING
Späth HM, Charavel M, Morelle M, Carrère MO
GRESAC - UMR 5823 du CNRS, Lyon, France
|
